Active substance
Methylprednisolone
- SFDA 27
- US FDA 99
- Health Canada 13
- US price lines 16
- NHS prices 8
- WHO EML 1
- Safety 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ADVANTAN 0.1% SKIN CREAM | 0.1 % | Cream · Topical | 1 Tube | SAR 18.20 | NCE · Prescription | LEO Pharma A/S Denmark | Valid |
| ADVANTAN 0.1% SKIN OINTMENT | 0.1 % | Ointment · Topical | 1 Tube | SAR 18.20 | NCE · Prescription | LEO Pharma A/S Denmark | Valid |
| DEPO MEDROL VIAL 40MG-ML SAS | 40 mg/ml | Suspension for injection · Intravenous use | 1 Vial | SAR 10.75 | NCE · Prescription | PFIZER | Valid |
| DEPO MEDROL VIAL 40MG-ML SAS | 40 mg/ml | Suspension for injection · Intravenous use | 1 Vial | SAR 19.55 | NCE · Prescription | PFIZER | Valid |
| EPIZOLONE DEPOT 40MG/ML VIAL | 40 mg/ml | Suspension for injection · Intraarticular use | 1 Vial | SAR 10.35 | Generic · Prescription | EIPICO | Valid |
| INTIDROL 125 MG LYOPHILISATE FOR SOLUTION FOR INJECTION | 125 mg | powder for solution for injection · Intramuscular and intravenous use | 1 Vial | SAR 25.80 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| INTIDROL 1GM LYOPHILISATE FOR SOLUTION FOR INJECTION | 1000 mg | powder for solution for injection · Intramuscular and intravenous use | 1 Vial | SAR 104.60 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| INTIDROL 40 MG LYOPHILISATE FOR SOLUTION FOR INJECTION | 40 mg | powder for solution for injection · Intramuscular and intravenous use | 1 Vial | SAR 10.40 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| INTIDROL 500 MG LYOPHILISATE FOR SOLUTION FOR INJECTION | 500 mg | powder for solution for injection · Intramuscular and intravenous use | 1 Vial | SAR 54.00 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| MEDROL 4 mg tablet | 4 mg | Tablet · Oral use | 30 Bottle | SAR 19.50 | NCE · Prescription | PFIZER | Valid |
| MEDROLONE 40 mg lyophilisate for solution for injection | 40 mg | Lyophilisate for solution for injection · Parenteral use | 1 Vial | SAR 10.85 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| MEDROLONE 500 mg lyophilisate for solution for injection | 500 mg | Lyophilisate for solution for injection · Parenteral use | 1 Vial | SAR 65.50 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| MEPROSON 40MG POWDER FOR INJECTION | 40 mg | powder for solution for injection · Intramuscular and intravenous use | 1 Vial | SAR 7.85 | Generic · Prescription | LES LABORATOIRES MEDIS | Valid |
| MEPROSON 500 MG POWDER FOR INJECTION | 500 mg | powder for solution for injection · Intramuscular and intravenous use | 10 Vial | SAR 258.50 | Generic · Prescription | LES LABORATOIRES MEDIS | Valid |
| Medrolone | 500 mg | Lyophilisate for solution for injection · Parenteral use | 10 Vial | SAR 655.00 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| SOLU-MEDROL 1000 mg powder and solvent for solution for injection | 1000 mg | Powder and solvent for solution for injection · Intramuscular and intravenous use | 1 Vial | SAR 116.20 | NCE · Prescription | PFIZER | Valid |
| SOLU-MEDROL INJ. 500 MG. | 500 mg | Powder and solvent for solution for injection · Intramuscular and intravenous use | 1 Vial | SAR 77.15 | NCE · Prescription | PFIZER | Valid |
| SOLU-MEDROL MOV 40 MG INJ. | 40 mg | Solution for injection · Intramuscular and intravenous use | 1 Vial | SAR 12.25 | NCE · Prescription | PFIZER | Valid |
| SOLU-MEDROL-INJ. 125 MG | 125 mg | Solution for injection · Intramuscular use | 1 Vial | SAR 30.35 | NCE · Prescription | PFIZER | Valid |
| ADVANTAN 0.1% SKIN CREAM | 0.1 % | Cream · Topical | 1 Tube | SAR 18.20 | NCE · Prescription | BAYER PHARMA AG | Withdrawn by MAH · Not Marketed |
| ADVANTAN 0.1% SKIN OINTMENT | 0.1 % | Ointment · Topical | 1 Tube | SAR 18.20 | NCE · Prescription | BAYER PHARMA AG | Withdrawn by MAH · Not Marketed |
| ADVANTAN 0.1% SKIN OINTMENT | 0.1 % | Ointment · Topical | 1 Tube | SAR 22.30 | NCE · Prescription | INTENDIS MANUFACTURING S.P.A. | Withdrawn by MAH · Not Marketed |
| ADVANTAN 0.1%SKIN CREAM | 0.1 % | Cream · Topical | 1 Tube | SAR 22.30 | NCE · Prescription | INTENDIS MANUFACTURING S.P.A. | Withdrawn by MAH · Not Marketed |
| MEDROL TAB 4 MG | 4 mg | Tablet · Oral use | 10 Blister | SAR 8.95 | NCE · Prescription | PFIZER | Withdrawn by MAH · Not Marketed |
| MEDROLONE 1000 mg lyophilisate for solution for injection | 1000 mg | Lyophilisate for solution for injection · Parenteral use | 1 Vial | SAR 89.20 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Withdrawn by MAH · Not Marketed |
2 more — full table
Indications — CHI Daman Drug Formulary
BEHCET DISEASE; ECZEMA; PSORIASIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; ULCERATIVE COLITIS; VITILIGO
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MEDROL | 4MG; 2MG; 16MG; 8MG; 32MG | tablet · oral | PFIZER | Prescription | 24 Oct 1957 |
| SOLU-MEDROL | EQ 40MG BASE/VIAL; EQ 125MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | PHARMACIA AND UPJOHN | Prescription | 18 May 1959 |
| DEPO-MEDROL | 40MG/ML; 20MG/ML; 80MG/ML | injectable · injection | PFIZER | Prescription | 27 May 1959 |
| METHYLPREDNISOLONE | 4MG | tablet · oral | WATSON LABS | Prescription | 16 Oct 1997 |
| METHYLPREDNISOLONE | 4MG; 8MG; 16MG; 32MG | tablet · oral | JUBILANT CADISTA | Prescription | 31 Oct 1997 |
| METHYLPREDNISOLONE | 4MG | tablet · oral | SANDOZ | Prescription | 31 Oct 1997 |
| METHYLPREDNISOLONE | 4MG | tablet · oral | PH HEALTH | Prescription | 22 Dec 1998 |
| METHYLPREDNISOLONE SODIUM SUCCINATE | EQ 40MG BASE/VIAL; EQ 125MG BASE/VIAL | injectable · injection | FRESENIUS KABI USA | Prescription | 30 Jul 2004 |
| METHYLPREDNISOLONE SODIUM SUCCINATE | EQ 1GM BASE/VIAL | injectable · injection | FRESENIUS KABI USA | Prescription | 12 Aug 2004 |
| METHYLPREDNISOLONE ACETATE | 40MG/ML; 80MG/ML | injectable · injection | EMERGE BIOSCIENCE | Prescription | 23 Feb 2005 |
| METHYLPREDNISOLONE ACETATE | 40MG/ML; 80MG/ML | injectable · injection | SANDOZ | Prescription | 29 Jan 2009 |
| METHYLPREDNISOLONE ACETATE | 40MG/ML; 80MG/ML | injectable · injection | SANDOZ | Prescription | 5 Mar 2009 |
| METHYLPREDNISOLONE SODIUM SUCCINATE | EQ 40MG BASE/VIAL; EQ 125MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | SAGENT PHARMS INC | Prescription | 18 Jul 2011 |
| METHYLPREDNISOLONE SODIUM SUCCINATE | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | HIKMA | Prescription | 16 Feb 2016 |
| METHYLPREDNISOLONE SODIUM SUCCINATE | EQ 40MG BASE/VIAL; EQ 125MG BASE/VIAL | injectable · injection | AMNEAL | Prescription | 9 Nov 2016 |
| METHYLPREDNISOLONE | 4MG; 8MG; 16MG; 32MG | tablet · oral | ZYDUS PHARMS | Prescription | 23 Apr 2018 |
| METHYLPREDNISOLONE | 4MG | tablet · oral | TIANJIN TIANYAO | Prescription | 14 May 2018 |
| METHYLPREDNISOLONE ACETATE | 40MG/ML; 80MG/ML | injectable · injection | SAGENT PHARMS INC | Prescription | 27 Jun 2018 |
| METHYLPREDNISOLONE ACETATE | 40MG/ML; 80MG/ML | injectable · injection | AMNEAL | Prescription | 20 May 2019 |
| METHYLPREDNISOLONE SODIUM SUCCINATE | EQ 40MG BASE/VIAL; EQ 125MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | TIANJIN KINGYORK | Prescription | 20 Apr 2021 |
| METHYLPREDNISOLONE ACETATE | 40MG/ML; 80MG/ML | injectable · injection | PH HEALTH | Prescription | 21 Jan 2022 |
| METHYLPREDNISOLONE SODIUM SUCCINATE | EQ 40MG BASE/VIAL; EQ 125MG BASE/VIAL | injectable · injection | HIKMA | Prescription | 26 Sep 2022 |
| METHYLPREDNISOLONE ACETATE | 80MG/ML; 40MG/ML | injectable · injection | WILSHIRE PHARMS INC | Prescription | 3 Jan 2023 |
| METHYLPREDNISOLONE ACETATE | 40MG/ML; 80MG/ML | injectable · injection | EUGIA PHARMA | Prescription | 13 Apr 2023 |
| METHYLPREDNISOLONE ACETATE | 40MG/ML; 80MG/ML | injectable · injection | AMNEAL | Prescription | 3 Nov 2023 |
74 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| DEPO-MEDROL | 00030759 | 40 MG / ML | SUSPENSION · INTRA-ARTICULAR; INTRALESIONAL; INTRASYNOVIAL; INTRAMUSCULAR | PFIZER CANADA ULC |
| DEPO-MEDROL | 00030767 | 80 MG / ML | SUSPENSION · INTRA-ARTICULAR; INTRALESIONAL; INTRAMUSCULAR; INTRASYNOVIAL | PFIZER CANADA ULC |
| DEPO-MEDROL | 01934325 | 20 MG / ML | SUSPENSION · INTRASYNOVIAL; INTRA-ARTICULAR; INTRAMUSCULAR; INTRALESIONAL | PFIZER CANADA ULC |
| DEPO-MEDROL | 01934333 | 40 MG / ML | SUSPENSION · INTRALESIONAL; INTRASYNOVIAL; INTRAMUSCULAR; INTRA-ARTICULAR | PFIZER CANADA ULC |
| DEPO-MEDROL | 01934341 | 80 MG / ML | SUSPENSION · INTRAMUSCULAR; INTRASYNOVIAL; INTRALESIONAL; INTRA-ARTICULAR | PFIZER CANADA ULC |
| MEDROL | 00030988 | 4 MG | TABLET · ORAL | PFIZER CANADA ULC |
| MEDROL | 00036129 | 16 MG | TABLET · ORAL | PFIZER CANADA ULC |
| SOLU-MEDROL | 00030678 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | PFIZER CANADA ULC |
| SOLU-MEDROL | 00036137 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | PFIZER CANADA ULC |
| SOLU-MEDROL | 02367947 | 40 MG / VIAL | POWDER FOR SOLUTION; KIT · INTRAVENOUS; INTRAMUSCULAR | PFIZER CANADA ULC |
| SOLU-MEDROL | 02367955 | 125 MG / VIAL | KIT; POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | PFIZER CANADA ULC |
| SOLU-MEDROL | 02367963 | 500 MG / VIAL | POWDER FOR SOLUTION; KIT · INTRAMUSCULAR; INTRAVENOUS | PFIZER CANADA ULC |
| SOLU-MEDROL | 02367971 | 1 G / VIAL | POWDER FOR SOLUTION; KIT · INTRAVENOUS; INTRAMUSCULAR | PFIZER CANADA ULC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | DEPO-MEDROL 40 MG/ML VIAL | $6.82706 | per ML | 23 Sep 2026 |
| US NADAC | DEPO-MEDROL 80 MG/ML VIAL | $11.65735 | per ML | 23 Sep 2026 |
| US NADAC | MEDROL 2 MG TABLET | $1.57028 | per EA | 23 Sep 2026 |
| US NADAC | MEDROL 4 MG DOSEPAK | $0.29107 | per EA | 23 Sep 2026 |
| US NADAC | MEDROL 4 MG TABLET | $0.2454 | per EA | 19 Aug 2026 |
| US NADAC | METHYLPREDNISOLONE 16 MG TAB | $1.44606 | per EA | 23 Sep 2026 |
| US NADAC | METHYLPREDNISOLONE 32 MG TAB | $2.75486 | per EA | 23 Sep 2026 |
| US NADAC | METHYLPREDNISOLONE 4 MG DOSEPK | $0.13607 | per EA | 23 Sep 2026 |
| US NADAC | METHYLPREDNISOLONE 4 MG TABLET | $0.12107 | per EA | 23 Sep 2026 |
| US NADAC | METHYLPREDNISOLONE 40 MG/ML VL | $7.49 | per ML | 23 Sep 2026 |
| US NADAC | METHYLPREDNISOLONE 400 MG/10 ML | $5.8078 | per ML | 22 Apr 2026 |
| US NADAC | METHYLPREDNISOLONE 8 MG TABLET | $0.93297 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Methylprednisolone 100mg tablets | £48.32 | 20 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Methylprednisolone 16mg tablets | £17.17 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Methylprednisolone 2mg tablets | £3.88 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Methylprednisolone 4mg tablets | £6.19 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Methylprednisolone acetate 120mg/3ml suspension for injection vials | £8.96 | 1 vial | 1 Oct 2026 |
| NHS Drug Tariff | Methylprednisolone acetate 40mg/1ml suspension for injection vials | £3.44 | 1 vial | 1 Oct 2026 |
| NHS Drug Tariff | Methylprednisolone acetate 80mg/2ml suspension for injection vials | £6.18 | 1 vial | 1 Oct 2026 |
| NHS Drug Tariff | Methylprednisolone sodium succinate 40mg powder and solvent for solution for injection vials | £1.58 | 1 vial | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 8.2.4. Hormones and antihormones · complementary
Burkitt lymphoma including Burkitt leukaemia; Lymphoid leukaemia, not elsewhere classified
Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) (EMLc); 125 mg in vial (as sodium succinate) (EMLc) | Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection (EMLc); 125 mg in vial (as sodium succinate) powder for injection (EMLc)
Safety signals and safety-related labeling changes
- US FDA 4 Nov 2025 SOLU-MEDROL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations - US FDA 4 Nov 2025 DEPO-MEDROL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - US FDA 4 Nov 2025 MEDROL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - EMA PRAC 6 Nov 2014 PRAC signal: Hepatotoxicity after high dose intravenous use
Action for MAH: update of the product information: No
Combinations containing Methylprednisolone
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.